Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease. Longeveron’s Phase I, prospective, randomized, placebo-controlled, double-blinded study is designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed Alzheimer’s disease. Longeveron has completed the FDA mandated safety run in and is now enrolling in the randomized cohort consisting of 25 subjects. The Alzheimer’s Associated awarded Longeveron a competitive grant award through its Part the Cloud Translational Research program in the amount of $1 million to complete this trial. This trial is critically important due to the proliferation of Alzheimer’s Disease and the lack of effective therapies to address it.
Alzheimer’s disease is a neurodegenerative disorder that leads to progressive memory loss and death. An estimated 5.3 million Americans are currently diagnosed, but there are few drugs available for treating Alzheimer’s disease, and none that affect the long-term progression of the disease. Barring significant medical breakthroughs, as many as 16 million Americans could be afflicted by the year 2050. Alzheimer’s disease is a neurodegenerative disorder that leads to progressive memory loss and death.
